MDClone, a leading data analytics and synthetic data company, and Thomas Jefferson University and Jefferson Health announced a partnership in which Jefferson will leverage MDClone’s innovative synthetic data platform to accelerate academic research.
The MDClone ADAMS Platform is a powerful, self-service data analytics environment that enables healthcare collaboration, research, and innovation. By making real-world data easier to access, the ADAMS Platform will help Jefferson researchers reduce the friction points to formulating academic research questions, identifying relevant data, analyzing the data, and producing results.
“Academic researchers face significant challenges in accessing healthcare data, such as siloed systems, long timelines, and complex data models,” said Billy Oglesby, Dean of the Jefferson College of Population Health. “Our collaboration with MDClone will create a more frictionless ecosystem for researchers to access clinical data, driving quicker timelines from idea to impact, including commercialization.”
Recommended AI: “Bitcoin Has No Intrinsic Value”. Then What Gives Bitcoin Value?
Jefferson’s clinical arm, Jefferson Health, is an 18-hospital health system based in Philadelphia that is home to nationally ranked experts. Jefferson’s Sidney Kimmel Cancer Center is one of only 70 National Cancer Institute-designated cancer centers in the country.
Jefferson’s partnership with MDClone is multifaceted.
First, the MDClone ADAMS platform will deliver streamlined workflows enabling Jefferson researchers to more easily access and analyze data from electronic health records, which is often difficult to access due to inconsistencies in the data and restrictive privacy regulations.
Recommended AI: Top 10 Countries and Cities by Number of CCTV Cameras
“MDClone’s state-of-the-art proprietary data synthesis process transforms patient-identifiable data into non-identifiable data while still retaining all the important statistical and contextual properties,” said Ziv Ofek, Founder and CEO of MDClone. “Using both discrete and non-discrete variables of interest, synthetic data does not contain identifiable information because it uses a statistical approach to create a data-set that is non-reversible and the only method that fully prevents re-identification.”
Next, the platform will provide Jefferson’s students with anonymous, real-world data they can use to test their own theories and explore their own strategies for population health improvement. Additionally, the platform will create new opportunities for Jefferson to partner with life sciences companies to inform and accelerate new therapeutic discoveries.
In addition to leveraging MDClone’s self-service exploration and synthetic data platform to create a faster path to knowledge generation for Jefferson researchers, the organizations have established a commercial collaboration to provide third-party organizations with access to Jefferson’s unique data assets. Through this arrangement, organizations such as life sciences companies and medical device manufacturers will gain the ability to discover insights to fuel the next generation of therapies, technologies, and solutions in a secure, efficient, and controlled environment.
“We are proud to continue our partnership with Jefferson as we work together to create a fundamentally different approach to unlocking the full value of healthcare data,” said Ofek.
Recommended AI: How is Artificial Intelligence (AI) Changing the Future of Architecture?
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.